Enfortumab Vedotin + Pembrolizumab + Quemliclustat for Bladder Cancer

This trial seeks to determine the optimal dose and evaluate the effectiveness of a combination of three treatments for bladder cancer that cannot be surgically removed and has spread. The treatments include enfortumab vedotin, which targets and kills cancer cells; pembrolizumab, which helps the immune system attack cancer; and quemliclustat, which may inhibit cancer cell growth. Individuals with metastatic bladder cancer who have not yet received treatment might be suitable candidates for this trial. As a Phase 1, Phase 2 trial, the research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking cancer research.

The trial protocol does not specify if you must stop taking your current medications, but it does mention a 'washout period' (time without taking certain medications) for other treatments. It's best to discuss your specific medications with the trial team.

Previous studies have shown that the combination of enfortumab vedotin and pembrolizumab has a manageable safety profile. Approximately 97% of patients experienced treatment-related side effects, with 57% facing severe ones. Common issues included skin problems and nerve damage, but no new safety concerns emerged over time.

Pembrolizumab alone is generally safe, with side effects such as low blood counts, but no severe immune-related problems. One study showed no deaths linked to pembrolizumab.

Quemliclustat, a newer drug, has been well-tolerated in early studies, although nearly all patients experienced some side effects. Severe side effects occurred in 73% of cases.

Researchers are excited about the combination of enfortumab vedotin, pembrolizumab, and quemliclustat for bladder cancer because each component brings a unique mechanism of action to the table. Enfortumab vedotin is an antibody-drug conjugate that specifically targets cancer cells, delivering a potent dose of chemotherapy directly to the tumor. Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells more effectively. Quemliclustat, a lesser-known agent, is being explored for its potential to modulate the tumor environment, possibly enhancing the effects of the other treatments. Together, these treatments offer a multifaceted approach that could potentially improve outcomes compared to standard therapies like chemotherapy or surgery alone.

Research has shown that combining enfortumab vedotin and pembrolizumab may effectively treat urothelial cancer. Studies have found that nearly 80% of patients experience a reduction in tumor size, and about 40% have no detectable cancer after treatment. This combination also significantly improves the time patients live without their cancer worsening and increases overall survival compared to chemotherapy. In this trial, participants will receive enfortumab vedotin, pembrolizumab, and quemliclustat. Early research on adding quemliclustat suggests it might enhance the treatment's effectiveness by blocking enzymes that cancer cells need to grow. These findings offer hope for better outcomes in bladder cancer patients.⁶⁷⁸⁹¹⁰